FilingSEC EDGAR6-K
Scinai Immunotherapeutics Discontinues PC111 Program and Refocuses Business
· SEC accepted
StageBusiness Restructuring
Filing content
Following the termination of the PC111 license agreement on August 31, the company announced it will refocus resources on its NanoAb platform and CDMO business.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…